IBP-9414 will be evaluated in preterm infants with a birth weight of 500-1500g, compared to placebo with regards to efficacy and safety in the prevention of necrotizing enterocolitis.

Conditions

  • Necrotizing Enterocolitis

Intervention

  • IBP-9414
  • Placebo

Principal Investigator

  • Fayard, Elba

Sponsor

  • Infant Bacterial Therapeutics AB

*The source of data for this particular study is "ClinicalTrials.gov" and was last updated on 06/05/2023. Loma Linda University does not make any warranties, expressed or implied, with respect to such data, and, furthermore, assumes no liability for any party's use, or the results of such use of the data.

Request Information

Complete the form below to contact the study team and receive more information about this trial.